Day Three - EST/EDT (Eastern Daylight, GMT-4)
Day Three - EST/EDT (Eastern Daylight, GMT-4)
- Paul Chen - Senior Director, Trade and Channel Management, Lexicon Pharmaceuticals
During this session, hear real life examples on implementing a Patient Services Program at an emerging oncology company and gain some insight on the preparation for a successful launch.
- Understand the importance of an internal and external needs assessment when building your program
- Discover best practices on creating a thoughtful and efficient Patient Support Program
- Learn how to develop a program that balances the needs of your company as well as your patients/providers
- Laurie Hart - Associate Director Market Access, Patient Services, Elevar Therapeutics
Today’s era of patient support services requires a hybrid approach, combining tech automation without comprising on human connection to deploy patient support services that make a difference. When operating effectively and with innovative technology, a suite of tailored patient support services can make it easier for players across pharma, providers, pharmacists, and payers to connect patients with the right support services they need to provide consistent medication access, affordability, and adherence for complex or chronic conditions.
- Kelly Martin - Vice President, Product Management, CoverMyMeds
- Gajanan Kulkarni - VP Product Management, CoverMyMeds
Dependent on the risk tolerance and incentive compensation built into your program, the rules of engagement between sales reps/field employees and your patient support/hubs teams can vary greatly. In this session, hear best practices on how to support your field team and ultimately drive improved patient care.
- Missie Scheffman - Region Director Reimbursement, West, Iveric Bio
Though a bit of a newer concept, digital therapeutics are here for the long game. With the promise to improve access to both care and novel treatments, their full potential has yet to be unleashed. During this session, take a deep dive into all that digital therapeutics have to offer, including the types of digital therapeutics as well as their regulatory considerations. Consider how different hub partners offer these services and their associated reimbursement challenges.
- Andy Molnar - CEO, Digital Therapeutics Alliance
- Discuss the history and current state of drug pricing regulation and legislation from both the federal and state level
- Understand the intersection of the impacts of health policy issues to PBMs and pharmaceutical manufacturers, including where the two entities align, despite other differences
- Caitlin Berry - Senior Principal, Public Policy and Government Affairs, Prime Therapeutics
Join us for an engaging benchmarking session that delves into the latest trends and strategies reshaping patient access, assistance, market access, pharmacy operations and rare disease management in the life sciences industry. Explore key metrics, best practices, and innovative approaches that are driving success in these critical areas. Gain valuable insights from industry leaders and benchmark your organization's performance against industry standards to uncover new opportunities for growth and improvement.
- Shawn Adeoye - Associate Director, Strategy, Patient Access and Affordability Solutions, Astellas